Decision

Advertising investigations: May 2021

Decisions made by MHRA following investigations into complaints about advertising for licensed medicines.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 27 August 2021

Documents

Promotion of Epilim (sodium valproate) by Sanofi

HTML

Details

Contact advertising@mhra.gov.uk if you have concerns with the advertising of medicines or write to:

Advertising Standards Unit,
10 South Colonnade
Canary Wharf
London
E14 4PU

Alternatively, contact the pharmaceutical self-regulatory bodies, the Proprietary Association of Great Britain (PAGB) for advertising for over the counter medicines, or the Prescription Medicines Code of Practice Authority (PMCPA) for advertisements to health professionals for prescription medicines.

See the Blue Guide for guidance on how medicines should be promoted or advertised in the UK.

Published 27 August 2021